Piper Sandler raised the firm’s price target on Argenx (ARGX) to $820 from $750 and keeps an Overweight rating on the shares following news that Vyvgart met its primary endpoint in the Phase 3 ADAPT SERON study in seronegative gMG patients, showing clinical improvement in MG-ADL across all three patient subtypes. A sBLA for Vyvgart is planned for year-end 2025, helping expand its reach to include about 20% of gMG patients classified as seronegative. With the PFS launch now underway, continued global expansion efforts, and additional nearterm opportunities for label expansions, Piper likes Vyvgart’s growth potential and continues to see upside for shares as the non-Vyvgart portfolio matures as well. Argenx remains a top pick for the firm and it continues to like the setup for 2025 and beyond.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx’s Vyvgart Shows Promising Phase III Results, Expanding Market Potential for Seronegative gMG Patients
- Argenx rises 6.0%
- Figma initiated, Okta upgraded: Wall Street’s top analyst calls
- argenx Reports Positive Results from ADAPT SERON Study for VYVGART
- Argenx announces ADAPT SERON study of Vyvgart met primary endpoint